<DOC>
	<DOCNO>NCT01116050</DOCNO>
	<brief_summary>Postpartum haemorrhage ( PPH ) remain major cause maternal mortality France . The efficient treatment severe PPH sulprostone associate cardiac complication . The objective study ass efficacy safety intrarectal misoprostol curative postpartum haemorrhage treatment . We conduct multicenter double blind randomize placebo control trial June 2004 December 2007 , among consent woman postpartum haemorrhage failure oxytocin treatment . Our main criterion judgement quantification blood loss use sulprostone two group use either misoprostol intrarectal tablet ( 5X200mg ) placebo similar opaque introducer .</brief_summary>
	<brief_title>Intrarectal Misoprostol Postpartum Haemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Postpartum Hemorrhage</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<criteria>Older 18 yr old Giving birth 32 Weeks amenorrhea Postpartum haemorrhage due atony Inefficiency first line treatment Written sign consent form know allergy prostaglandin haemostasis anomalies labour anticoagulant treatment fetal death accreta percreta placenta 18 year delivery 32 week amenorrhea postpartum bleed suspect due atonic uterus</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>